Navigation Links
Vantia Therapeutics' Pipeline Continues to Mature
Date:3/24/2009

SOUTHAMPTON, England, March 24 /PRNewswire/ --

- VA106483 Completes Phase IIa Trial and VA111913 Completes Phase I Dosing

Vantia Therapeutics, a company focusing on first-in-class therapies for unmet medical needs, announces further clinical trial progress with its two lead development compounds, VA106483 for nocturia associated with benign prostatic hypertrophy (BPH) and VA111913 for dysmenorrhoea. The Phase IIa trial of VA106483 has completed, while dosing is complete in the Phase I trial of VA111913. With this news and developments in Vantia's preclinical pipeline, the company is continuing to generate value from its extensive library of small molecule antagonists of hormones and proteases.

Following the completion of the 27-patient Phase IIa trial of VA106483, a vasopressin agonist, results are expected in H1 2009, with the Phase IIb study expected to start in the second half of the year. Up to 200 males with nocturia are expected to be involved in this dose-finding placebo-controlled study, which is expected to complete in the first half of 2010.

Given Vantia Therapeutics' strategy of developing products to the end of proof of concept/Phase IIb trials, the product is expected to be outlicensed for further development after the Phase IIb results. Nocturia in BPH is believed to represent a potential market in excess of $1bn, and VA106483's potential in follow-on indications such as overactive bladder and general nocturia could add significant extra value.

The Phase I trial for VA111913 has recruited the last of its 99 volunteers, and is also expected to report data in H1 2009. Phase IIa trials are expected to start in the second half of this year, involving over 100 patients and completing in H2 2010. VA111913 is a vasopressin antagonist, with dysmenorrhoea (painful menstruation) believed to represent a multibillion dollar market for which there is currently no t
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015   The New ... injection, Kybella, from internationally acclaimed plastic surgeon, Dr. ... and Drug Administration, is proven to reduce fat deposits ... The active ingredient in Kybella, ... gives plastic surgeons the ability to reshape this area ...
(Date:5/4/2015)... N.J. , May 4, 2015 Thirty-six ... percent seek help. During May – National Hearing Month ... loss could be missing out on the sounds of ... the trees. To ensure that you won,t ... that color our world, Oticon, Inc. offers practical advice: ...
(Date:5/4/2015)... May 4, 2015 PAREXEL International Corporation (NASDAQ: ... the UBS Healthcare Conference on Monday, May 18, 2015, in ... and Chief Financial Officer will be making a presentation on ... A live webcast of the presentation will be available ... in the Upcoming Events portion of the main page, ...
Breaking Medicine Technology:Dr. Rod Rohrich Provides Medical Expertise on Kybella 2Dr. Rod Rohrich Provides Medical Expertise on Kybella 3It's Better Hearing Month 2PAREXEL International to Present at UBS Healthcare Conference 2
... Nov. 11 Shire plc ... biopharmaceutical company, today announced the re-launch of FOCUS ( ... patient support program for adults taking once-daily Vyvanse ... treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded ...
... Deloitte Recap LLC (Recap) has launched "Development ... Series by Deloitte. The series of biopharmaceutical business ... service tailored toward business development, corporate strategy, financial, ... , "Development Optimizer" provides flexible analytical tools for ...
Cached Medicine Technology:Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII 2Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII 3Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII 4Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII 5Deloitte Recap Launches New Solution for Clinical Development 2Deloitte Recap Launches New Solution for Clinical Development 3
(Date:5/4/2015)... York, NY (PRWEB) May 04, 2015 ... specialized insurance programs, announces the expansion of coverage for ... is a leading provider of industry-tailored insurance and proactive ... McNeil & Company, we are dedicated to providing our ... to meet their many evolving needs. We are excited ...
(Date:5/4/2015)... Healthcare Solutions is proud to be a sponsor at ... in Baltimore, MD from May 11 – 13, 2015. ... opportunity for clients to gather to network, attend educational ... to sponsoring the event, TROY Healthcare Solutions will be ... can stop by the TROY booth and see sample ...
(Date:5/4/2015)... 2015 Baptist Medical Center Jacksonville ... Get With The Guidelines®-Stroke Gold Plus Quality Achievement ... The award recognizes the hospital’s commitment and success ... appropriate treatment according to nationally recognized, research-based guidelines ... receive the Gold Plus Quality Achievement Award, hospitals ...
(Date:5/4/2015)... Now in its seventh year, the IPC ... made outstanding contributions to the company, to their facilities ... and post-acute care settings. The five award categories are: ... Year, Advanced Practice Clinician of the Year, Newcomer Provider ... Recipients are selected by IPC’s senior management team. , ...
(Date:5/4/2015)... Los Angeles, CA (PRWEB) May 04, 2015 ... Kevin Sands, is now offering a more comfortable and ... been the restoration of choice for those who have ... patients. Dentures can feel insecure or slip at the ... the patient eats or talks. They can also painfully ...
Breaking Medicine News(10 mins):Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2
... (HealthDay News) -- A certain area of the cerebral cortex ... smoked, finds a new study. The cerebral cortex is ... in reward, impulse control and decision making. German researchers ... smokers and 21 people who never smoked. Using these images, ...
... work night and rotating shifts are almost twice as likely ... day shifts, according to a study by researchers at the ... current issue of the Scandinavian Journal of Work, Environment ... collected as part of Statistics Canada,s Survey of Labour and ...
... HealthDay Reporter , MONDAY, Nov. 1 (HealthDay News) -- There may ... exercise regularly seem to have fewer and milder colds, a new ... catch a cold two to four times a year, and children ... colds sap about $40 billion from the U.S. economy in direct ...
... cancer, one of the most prevalent cancers in women, ... about 40,000 deaths annually. The disease often extends to ... process in which cancer cells invade blood vessels or ... prognosis for patients. Some scientists argue that evidence ...
... Nov. 2 (HealthDay News) -- Extroverts are more vulnerable to ... social activity than after they,ve been alone, researchers have found. ... and 25 introverts (reserved, shy types), aged 18 to 39, ... or a "socially impoverished group." Those in the socially ...
... New York, NY, November 2, 2010An initiative by the ... of proven value less expensive for their employees succeeded ... to a Commonwealth Fund-supported study published in this month,s ... by Niteesh K. Choudhry at Brigham and Women,s Hospital, ...
Cached Medicine News:Health News:Shift work linked to higher risk of work injury: UBC study 2Health News:Exercise May Help Beat the Common Cold 2Health News:Exercise May Help Beat the Common Cold 3Health News:Fox Chase researchers identify risk factors for the spread of breast cancer to lymph nodes 2Health News:Socializing Tied to Sleep Deprivation in Extroverts 2Health News:Eliminating or reducing cost-sharing for high-value prescription drugs improves medication use 2
MAMMOMAT 3000 Nova supports high-volume screening as well as interventional diagnostics. Versatile procedural capabilities include magnification, stereotactic biopsy, needle localization, and specime...
Since 1964, in its plants of Sesto Fiorentino, Sbisà produces a wide and qualified range of instruments for ophthalmology and optometry....
Single-use, non-sterile...
Inquire...
Medicine Products: